Dronabinol

Generic Name: Dronabinol

Brand Names: Marinol, Sativex, Syndros

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 1972-08-3

Unique Ingredient Identifier: 7J8897W37S

Background: Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...

Indication: Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions: Anorexia, Chemotherapy-Induced Nausea and Vomiting

Associated Therapies: -

Clinical Trials

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Phase 2

Not yet recruiting

Conditions: Breast Carcinoma
Chemotherapy-Induced Peripheral Neuropathy
Colon Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Cannabidiol
Other: Survey Administration
Drug: Dronabinol
Drug: Placebo Administration

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-13

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 120

Registration Number: NCT06731894

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States

Pilot FMRI Studies of Aging-Related Effects of THC

Phase 2

Not yet recruiting

Conditions: THC

Interventions: Drug: THC
Drug: Placebo

First Posted Date: 2024-10-17

Last Posted Date: 2024-11-12

Lead Sponsor: Yale University

Target Recruit Count: 10

Registration Number: NCT06647524

Locations: 🇺🇸
Olin Neuropsychiatric Research Center at Hartford Healthcare, Hartford, Connecticut, United States

DRonabinol Treatment of OSA

Phase 1

Not yet recruiting

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Dronabinol

First Posted Date: 2024-06-27

Last Posted Date: 2024-10-26

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 120

Registration Number: NCT06477952

Locations: 🇺🇸
Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States

Dronabinol as an Adjunct for Reducing Pain

Phase 2

Recruiting

Conditions: Low Back Pain
Back Injuries
Chronic Pain

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2024-06-12

Last Posted Date: 2024-08-06

Lead Sponsor: Christopher D. Verrico

Target Recruit Count: 75

Registration Number: NCT06454669

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Warrior CARE: Cannabis Behavioral Health

Phase 1

Not yet recruiting

Conditions: Post Traumatic Stress Disorder
Cannabis Use
Suicide
Veterans
Marijuana

Interventions: Drug: Tetrahydrocannabinol
Drug: Cannabidiol
Drug: Placebo

First Posted Date: 2024-04-24

Last Posted Date: 2024-07-23

Lead Sponsor: Wayne State University

Target Recruit Count: 500

Registration Number: NCT06381180

Locations: 🇺🇸
Wayne State University, Detroit, Michigan, United States

Behavioral Pharmacology of Orally Administered THC and D-limonene

Phase 1

Not yet recruiting

Conditions: Subjective Drug Effects
D-limonene
THC

Interventions: Drug: Placebo
Drug: Delta-9-THC
Drug: D-Limonene

First Posted Date: 2024-04-23

Last Posted Date: 2024-12-04

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 65

Registration Number: NCT06378957

Locations: 🇺🇸
Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Cannabis (THC vs. CBD) in Multiple Sclerosis

Phase 2

Not yet recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: THC
Drug: CBD

First Posted Date: 2024-02-15

Last Posted Date: 2024-02-15

Lead Sponsor: University of Calgary

Target Recruit Count: 30

Registration Number: NCT06261489

High Confusion: Cannabis & Driving

Early Phase 1

Recruiting

Conditions: Impairment, Psychomotor
Impairment, Cognitive
Impairment of Attention

Interventions: Drug: Delta-8-THC
Drug: Placebo
Drug: Delta-9-THC

First Posted Date: 2024-02-01

Last Posted Date: 2024-12-06

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 5

Registration Number: NCT06236815

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance

Phase 1

Recruiting

Conditions: Cannabis

Interventions: Drug: Delta-8-THC
Drug: Placebo
Drug: Delta-9-THC

First Posted Date: 2024-01-23

Last Posted Date: 2024-07-31

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 45

Registration Number: NCT06218550

Locations: 🇺🇸
Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients with OSA

Phase 2

Recruiting

Conditions: Obstructive Sleep Apnea

Interventions: Drug: IHL-42X High Dose
Drug: Placebo
Drug: IHL-42X (Optimal Dose)
Drug: IHL-42X Low Dose
Drug: Dronabinol
Drug: Acetazolamide

First Posted Date: 2023-11-24

Last Posted Date: 2024-12-02

Lead Sponsor: Incannex Healthcare Ltd

Target Recruit Count: 560

Registration Number: NCT06146101

Locations: 🇺🇸
Desert Center for Allergy and Chest Diseases, Pheonix, Arizona, United States
🇺🇸
Exalt Clinical Research, Chula Vista, California, United States
🇺🇸
CenExel CNS- Los Alamitos, Long Beach, California, United States

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy